Luoqi Biological

Shanghai Luoqi Biological Technology (Luoqi Biotech) is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative nanobody-based therapeutics. Founded in 2017, the company leverages its proprietary Nova-VHH nanobody library and a specialized inhaled biologics platform to address unmet needs in respiratory and immunological diseases. Its lead candidate, LQ036, is a first-in-class inhaled nanobody targeting IL-4Rα for the treatment of moderate-to-severe asthma, currently in Phase 2 clinical trials. Luoqi Biotech's technology focuses on the unique structural advantages of single-domain antibodies, such as high stability and the ability to be delivered directly to the lungs via nebulization. The company aims to provide more effective and convenient treatment options for patients with chronic inflammatory conditions.